SpringWorks Therapeutics, Inc. Selected Balance Sheet Data(Unaudited) September 30, 2023 December 31, 2022 (in thousands) Cash, cash equivalents and marketable securities $ 422,419 $ 597,006 ...

SpringWorks Therapeutics is launching a new disease state education campaign at DesmoidTumors.com. The clinical-stage biotech, which is working on medicines to help patients suffering from rare ...

The European Commission has approved EZMEKLY (mirdametinib) for treatment of symptomatic, inoperable plexiform neurofibromas ...

Get the latest news on SpringWorks Therapeutics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on SWTX performance ...

--SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that it has commenced an underwritten public offering of ...

About SpringWorks Therapeutics At SpringWorks, a clinical-stage biopharmaceutical company, we are driven to develop life-changing medicines for patients with severe rare diseases and cancer.

Current Position of SpringWorks Therapeutics Trading volume stands at 363,208, with SWTX's price down by -2.76%, positioned at $58.27. RSI indicators show the stock to be may be overbought.

SpringWorks is using Nirogacestat, while AbbVie provides ABBV-383. It is believed that Nirogacestat provides a boost for BCMA therapies like ABBV-383. This isn't the first partnership for SpringWorks.

SpringWorks is committed to improving our understanding of desmoid tumors. There’s a significant need for more education and we are working with urgency and tenacity to help improve the outcomes for ...

Springworks is not an ordinary farm. Founded in 2014 by 19-year-old Trevor Kenkel, Springworks grows lettuce and raises fish in a complex, closed system of circulating water.

Springworks, located off Route 196, is proposing a 26,000-square-foot greenhouse and a 14,000-square-foot building that should roughly triple the production of lettuce and salad greens.

STAMFORD, Conn., May 03, 2023 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for ...